The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality From COVID-19.
COVID-19
alpha-1-adrenergic receptor antagonist
coronavirus disease
infectious disease
off-label drug use
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2021
2021
Historique:
received:
04
12
2020
accepted:
25
02
2021
entrez:
19
4
2021
pubmed:
20
4
2021
medline:
20
4
2021
Statut:
epublish
Résumé
Effective therapies for coronavirus disease 2019 (COVID-19) are urgently needed, and pre-clinical data suggest alpha-1 adrenergic receptor antagonists (α
Identifiants
pubmed: 33869251
doi: 10.3389/fmed.2021.637647
pmc: PMC8048524
doi:
Types de publication
Journal Article
Langues
eng
Pagination
637647Commentaires et corrections
Type : UpdateOf
Informations de copyright
Copyright © 2021 Rose, Graham, Koenecke, Powell, Xiong, Shen, Mench, Kinzler, Bettegowda, Vogelstein, Athey, Vogelstein, Konig and Wagner.
Déclaration de conflit d'intérêts
In 2017, The Johns Hopkins University (JHU) filed a patent application on the use of various drugs to prevent cytokine release syndromes, on which BV and KK are listed as inventors. JHU will not assert patent rights from this filing for treatment related to COVID-19. MK received personal fees from Bristol-Myers Squibb and Celltrion, unrelated to the manuscript. BV and KK are founders of and hold equity in Thrive Earlier Detection. KK is a consultant to and is on the Board of Directors of Thrive Earlier Detection. BV and KK are founders of, hold equity in, and serve as consultants to Personal Genome Diagnostics. KK and BV are consultants to Sysmex, Eisai, and CAGE Pharma and hold equity in CAGE Pharma. BV is also a consultant to Nexus. KK and BV are consultants to and hold equity in NeoPhore. CB is a consultant to Depuy-Synthes and Bionaut Pharmaceuticals. CB, BV, and KK are also inventors on technologies unrelated or indirectly related to the work described in this article. Licenses to these technologies are or will be associated with equity or royalty payments to the inventors, as well as to JHU. The terms of all these arrangements are being managed by JHU in accordance with its conflict of interest policies. SA is an advisor and holds an equity stake in two private companies, Prealize (Palo Alto, California, USA) and Dr. Consulta (Brazil). Prealize is a healthcare analytics company, and Dr. Consulta operates a chain of low-cost medical clinics in Brazil. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet Rheumatol. 2020 Oct;2(10):e594-e602
pubmed: 32864628
N Engl J Med. 2021 Mar 4;384(9):795-807
pubmed: 33306283
J Clin Invest. 2020 Jul 1;130(7):3345-3347
pubmed: 32352407
N Engl J Med. 2021 Jan 7;384(1):20-30
pubmed: 33332779
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Lancet Rheumatol. 2020 Dec;2(12):e754-e763
pubmed: 33015645
Anesthesiology. 2014 May;120(5):1192-204
pubmed: 24614323
J Pharmacol Exp Ther. 2011 Aug;338(2):648-57
pubmed: 21571945
Nature. 2007 Oct 11;449(7163):721-5
pubmed: 17914358
Proc Natl Acad Sci U S A. 1985 Sep;82(17):5915-9
pubmed: 2994053
Arthritis Rheumatol. 2020 Jul;72(7):1059-1063
pubmed: 32293098
J Neuroimmunol. 1996 Dec;71(1-2):223-6
pubmed: 8982123
Acta Med Okayama. 2013;67(4):245-51
pubmed: 23970323
Cytokine. 2015 Apr;72(2):210-9
pubmed: 25703786
N Engl J Med. 2020 Dec 3;383(23):2255-2273
pubmed: 33264547
N Engl J Med. 2003 Dec 18;349(25):2387-98
pubmed: 14681504
Stat Sci. 2010 Feb 1;25(1):1-21
pubmed: 20871802
Mol Med Rep. 2018 Feb;17(2):2145-2152
pubmed: 29207167
Am J Psychiatry. 2013 Sep;170(9):1003-10
pubmed: 23846759
Curr Top Membr. 2011;67:113-38
pubmed: 21771488
Nature. 2018 Dec;564(7735):273-277
pubmed: 30542164